US and UK Strike Tariff-Free Arrangement on Drugs.
The United Kingdom and the United States have concluded a landmark commercial pact that will guarantee no tariffs on British drug products being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has committed to raise expenditure on medicines through the NHS. This pledge guarantees that duties on these key exports will stay at zero for a period of the next three years.
This deal comes after recent statements to significantly raise tariffs on patented drug products, with increases floated up to one hundred percent.
"This deal with the Britain strengthens the international landscape for innovative medicines and establishes much-needed equity to transatlantic pharmaceutical trade," a release said.
Economic Importance
Pharmaceuticals are one of the Britain's most significant exports to the United States, which is by far the biggest buyer for major UK drugmakers.
Trade data reveal that in the one-year period prior to last September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of British export trade in that span.
"This agreement safeguards employment, stimulates investment and facilitates the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Detailed British Pledges
The deal entails several key changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at 15%. In the past, rebates were more than 20%.
Broader Context
The deal follows a long-running dispute between the drug companies and the UK government over medicine costs and NHS adoption.
These tensions were intensified by arguments that American consumers were charged significantly more for the same drugs than patients in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or abandoned, while substantial expansions have been announced toward US facilities.
One official publicly accepted that the NHS must spend more on medicines, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
